Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1596256 | 0.84 | SYK (0.40) | SYKMAPTCTSLCTSS | |
| SCHEMBL3722611 | 0.84 | SYK (0.50) | SYK | |
| SCHEMBL13434967 | 0.81 | SIRT2 (0.53) | SYKCTSLCTSSSIRT2SIRT1 | |
| SCHEMBL3902571 | 0.81 | SIRT2 (0.53) | SYKCTSLCTSSSIRT2SIRT1 | |
| SCHEMBL133032 | 0.81 | SIRT2 (0.53) | SYKCTSLCTSSSIRT2SIRT1 | |
| SCHEMBL1596691 | 0.81 | CTSL (0.52) | SYKCTSLCTSSSIRT2SIRT1 | |
| SCHEMBL8054994 | 0.80 | SIRT2 (0.55) | SYKCTSLCTSSSIRT2SIRT1 | |
| SCHEMBL6024571 | 0.80 | L3MBTL1 (0.41) | — | |
| SCHEMBL25002520 | 0.78 | SYK (0.53) | SYKMAPTCTSL | |
| SCHEMBL3319289 | 0.78 | CTSL (0.56) | SYKMAPTCTSLCTSSSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-7019003-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1363873-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | disclosed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087585-A1 | Peptide deformylase inhibitors | PDF, DPEP1, PEPD | SYK 4093/4885MAPT 3406/4885CTSL 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.